Trials
7 active
8 in total · 7 in the EU
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 1
- “This is a randomised, double-blind, two-arm, parallel group, single-dose study to compare the pharmacokinetics, safety, tolerability, and immunogenicity of ixekizumab (SB35 and Taltz) in healthy participants.”In the company’s words, NCT07789964 on ClinicalTrials.gov
- Other names
- Ixekizumab
Coming up1
- 9 Jun 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 9 Jun 2027 | A Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of SB35 (Proposed Ixekizumab Biosimilar) to Taltz in Healthy Participants | |
| Phase 3Authorised | not given | Clinical and ultrasound assessment of the therapeutic response to ixekizumab in psoriatic arthritis dactlylitis; a multicentre, parallel-groups, randomised controlled trial | |
| Phase 3Authorised | not given | A prospective, randomized, controlled, open label, assessor-blinded, parallel-group Phase III clinical trial to evaluate the impact of tapering systemic immunosuppressive therapy in a treat-to-target approach on maintaining minimal disease activity in adult subjects with psoriatic arthritis | |
| Phase 2Authorised | not given | A randomized placebo controlled clinical trial of preserving endogenous insulin production with Ixekizumab in newly diagnosed persons with type 1 diabetes | |
| Phase 4Ended | not given | Rapid pain control in Ixekizumab targeted axial spondyloarthritis | |
| Phase 4Authorised | not given | Proactive therapeutic drug monitoring versus routine care with the novel biologics in psoriasis: a pragmatic, multicentric, randomised, controlled study (HELIOS) | |
| Phase 4Authorised | not given | Detailed assessment of axial and peripheral entheses and joints in axial spondyloarthritis and psoriatic arthritis patients treated with ixekizumab – a 2-year study applying whole-body MRI, MRI-based synthetic CT, and CT | |
| Phase 4Authorised | not given | IDENTIFICATION OF SYNOVIAL BIOMARKERS OF RESPONSE TO IXEKIZUMAB IN REFRACTORY PSORIATIC ARTHRITIS: THE PRECISE STUDY. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026